Previous Close | 7.89 |
Open | 7.90 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 7.82 - 7.90 |
52 Week Range | 2.73 - 7.90 |
Volume | |
Avg. Volume | 2,675 |
Market Cap | 104.176M |
Beta (5Y Monthly) | 0.75 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months: New strategic partnership with AbbVie for OSE-230, a novel preclinical potential first-in-class program for the treatment of chronic inflammation. Major partnership expansion with Boehringer Ingelheim: Amendment of the collaboration and licensing agreement on first-in-class SIRPα compounds already developed in immuno-oncology, now expected in Phase 2 in cardiovascula
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases Nantes, France - Ingelheim, Germany - 22 May 2024, 7:30am CET - Today OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Boehringer Ingelheim announced a major expansion of their partnership. Two new projects to develop first-in-class treatments will be added to the ongoing anti-SIRPα immuno-oncology programs. The first involves broa
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global license with AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the